The deadline to submit an abstract for short talk and poster presentation consideration has passed. For any questions or issues, please email info@keystonesymposia.org.

Antibodies have become the most successful and versatile class of biological drugs with well over 100 therapeutic antibodies approved for human use. Antibody engineering for optimized and novel functionalities is providing unprecedented opportunities in our quest to develop innovative treatments for a wide variety of diseases. In recent years, engineered antibody formats have matured from research to clinical stage molecules with engineered antibodies currently representing about 40% of the 1,000+ antibodies in clinical development. This conference will review the translation of fundamental insights in both antibody and pathological mechanisms into next generation therapeutics and will discuss the opportunities and challenges ahead.